Maxim Group Maintains a Buy Rating on Semler Scientific (SMLR), Sets a $95 PT

Semler Scientific, Inc. (NASDAQ:SMLR) is one of the best medical device stocks to buy according to analysts. Analyst Matthew Galinko of Maxim Group maintained a Buy rating on  Semler Scientific, Inc. (NASDAQ:SMLR) on August 6, retaining the price target of $95.00.

The analyst told investors that Semler Scientific, Inc. (NASDAQ:SMLR) has exhibited a strong commitment to the accumulation of Bitcoin, with a goal to hold 10,000 BTC by the end of 2025 and considerably more in the following years.

He added that Semler Scientific, Inc.’s (NASDAQ:SMLR) ability to raise considerable funds through share issuance further supports this accumulation strategy, suggesting a strong financial strategy.

Galinko further stated that Semler Scientific, Inc. (NASDAQ:SMLR) is also expanding its medical technology offerings, especially with the formation of CardioVanta, a subsidiary focused on cardiovascular market opportunities. The expected approval of new diagnostic devices may expand the company’s market reach, enhancing its revenue potential.

Semler Scientific, Inc. (NASDAQ:SMLR) provides technology and software solutions to improve the clinical effectiveness of healthcare providers. The company’s multi-test service platform, WellChec, conducts a comprehensive evaluation of patients for chronic disease, including strokes and heart attacks, through the use of its QuantaFlo product as well as other tests.

While we acknowledge the potential of SMLR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.